Sign In
Buy RPID
Rapid Micro Biosystems Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.250 |
| EPS actual | -$0.310 |
| EPS Surprise | -24.00% |
| Revenue estimate | 7.6M |
| Revenue actual | 8.002M |
| Revenue Surprise | 5.29% |
| Release date | Mar 12, 2026 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.280 |
| EPS Surprise | -21.74% |
| Revenue estimate | 11.35M |
| Revenue actual | 11.282M |
| Revenue Surprise | -0.599% |
| Release date | Nov 07, 2025 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.260 |
| Revenue estimate | 10.933M |
| Revenue actual | 7.838M |
| Revenue Surprise | -28.31% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.270 |
| EPS Surprise | -3.85% |
| Revenue estimate | 8.333M |
| Revenue actual | 7.262M |
| Revenue Surprise | -12.86% |
Last 4 Quarters for Rapid Micro Biosystems
Below you can see how RPID performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $2.68 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.270 |
| EPS surprise | -3.85% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $3.41 |
| Aug 07, 2025 | $3.35 |
| Aug 08, 2025 | $3.40 |
| Aug 11, 2025 | $3.26 |
| Aug 12, 2025 | $2.68 |
| Aug 13, 2025 | $2.91 |
| Aug 14, 2025 | $2.82 |
| Aug 15, 2025 | $2.62 |
| Aug 18, 2025 | $2.65 |
| 4 days before | -21.41% |
| 4 days after | -1.12% |
| On release day | 8.58% |
| Change in period | -22.29% |
| Release date | Nov 07, 2025 |
| Price on release | $3.10 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.260 |
| Date | Price |
|---|---|
| Nov 03, 2025 | $2.75 |
| Nov 04, 2025 | $2.70 |
| Nov 05, 2025 | $2.87 |
| Nov 06, 2025 | $2.75 |
| Nov 07, 2025 | $3.10 |
| Nov 10, 2025 | $3.24 |
| Nov 11, 2025 | $3.76 |
| Nov 12, 2025 | $4.14 |
| Nov 13, 2025 | $4.46 |
| 4 days before | 12.73% |
| 4 days after | 43.87% |
| On release day | 4.52% |
| Change in period | 62.18% |
| Release date | Mar 12, 2026 |
| Price on release | $3.43 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.280 |
| EPS surprise | -21.74% |
| Date | Price |
|---|---|
| Mar 06, 2026 | $4.12 |
| Mar 09, 2026 | $4.20 |
| Mar 10, 2026 | $4.13 |
| Mar 11, 2026 | $4.38 |
| Mar 12, 2026 | $3.43 |
| Mar 13, 2026 | $2.83 |
| Mar 16, 2026 | $2.97 |
| Mar 17, 2026 | $2.92 |
| Mar 18, 2026 | $2.68 |
| 4 days before | -16.87% |
| 4 days after | -21.75% |
| On release day | -17.37% |
| Change in period | -34.95% |
| Release date | May 13, 2026 |
| Price on release | $2.48 |
| EPS estimate | -$0.250 |
| EPS actual | -$0.310 |
| EPS surprise | -24.00% |
| Date | Price |
|---|---|
| May 07, 2026 | $2.56 |
| May 08, 2026 | $2.63 |
| May 11, 2026 | $2.58 |
| May 12, 2026 | $2.58 |
| May 13, 2026 | $2.48 |
| May 14, 2026 | $2.32 |
| May 15, 2026 | $2.07 |
| May 18, 2026 | $1.96 |
| May 19, 2026 | $1.98 |
| 4 days before | -3.13% |
| 4 days after | -20.16% |
| On release day | -6.45% |
| Change in period | -22.66% |
Rapid Micro Biosystems Earnings Call Transcript Summary of Q1 2026
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M, up 11% year-over-year, driven by 6 Growth Direct system placements (196 systems placed globally, 160 validated) and strong consumables usage. Product revenue rose 36% (record consumables growth >30%), recurring revenue grew 28% and represented 63% of total revenue. Q1 gross margin was 5%, improving 8 points sequentially; management expects an inflection to positive product gross margins beginning in Q2 and reiterates full-year 2026 revenue guidance of $37M–$41M with 30–38 system placements and at least 25 validations. Full-year gross margin target is approx. 20% with a Q4 exit in the mid-20% range; Q2 gross margin is expected in the mid- to high-teens. The company highlighted progress on consumable cost reductions, manufacturing efficiencies and a strategic distribution & services collaboration with MilliporeSigma (including exclusive validation/maintenance services to MilliporeSigma customers). Q1 net loss was $14.3M; operating expenses rose to $14.2M (including $0.9M one-time severance). Cash used was $15M in Q1; ending cash was $23M with $25M of remaining availability under the Trinity credit facility. Management expects sequential cash use improvement through 2026 and reiterated disciplined capex and expense management (full-year OpEx guide $48M–$52M, CapEx ~$2M).
